How does OncuraKit complement prostate-specific antigen (PSA) testing?

PSA testing has well-known limitations: it has a high false-positive rate (many men with elevated PSA do not have prostate cancer — benign prostatic hyperplasia and prostatitis also raise PSA), leading to unnecessary biopsies. Conversely, some prostate cancers do not significantly elevate PSA. OncuraKit measures different molecular signals (miR-21, miR-375, miR-141) that are elevated in prostate cancer regardless of PSA level. OncuraKit is particularly valuable for men who have received an inconclusive or borderline PSA result (typically 4–10 ng/mL) and want additional information before deciding whether to proceed with a prostate biopsy. A positive OncuraKit result in this context strengthens the case for further evaluation; a negative result provides additional reassurance. OncuraKit does not replace PSA testing but complements it.